Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567546 | 1.00 | LMNA (0.50) | LMNATDP1CHRNB2CHRNA4CHRNB4 | |
| Formic Acid Methyl Ester SCHEMBL31373300 | 0.86 | KMT2A (0.40) | LMNATDP1CHRNB2CHRNA4CHRNB4 | |
| Propionic Acid SCHEMBL28238586 | 0.83 | CCNC (0.45) | LMNACHRNB2CHRNA4 | |
| SCHEMBL29139327 | 0.83 | LMNA (0.47) | LMNATDP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30297760 | 0.79 | DRD1 (0.33) | LMNATDP1ALDH1A1 | |
| SCHEMBL28047515 | 0.79 | CYP3A4 (0.54) | LMNACYP19A1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL28760545 | 0.78 | LMNA (0.50) | LMNATDP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4946642 | 0.78 | CHRNB2 (0.51) | LMNATDP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29854164 | 0.78 | CHRNB2 (0.51) | LMNATDP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL27732729 | 0.77 | LMNA (0.42) | LMNATDP1CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| WO-2022101265-A1 | PESTICIDALLY ACTIVE FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2022-05-19 | — | — | WO | claimed |
| CN-105431420-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2019-08-13 | — | — | CN | claimed |
| WO-2016012384-A1 | TRIFLUORMETHYLOXAZINE AMIDINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-28 | — | — | WO | claimed |
| EP-4643644-A2 | PESTICIDALLY ACTIVE FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | Syngenta Crop Protection AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4069688-B1 | PESTICIDALLY ACTIVE FUSED BICYCLIC HETEROAROMATIC AMINO COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4051673-B1 | PESTICIDALLY ACTIVE FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| EP-4590397-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| CN-114630825-B | Condensed with pesticidal activity bicyclic heteroaromatic compounds | 先正达农作物保护股份公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-115003666-B | Condensed derivatives of pesticidal activity Cyclic heteroaromatic amino compounds | 先正达农作物保护股份公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240327397-A1 | Pesticidally Active Fused Bicyclic Heteroaromatic Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-03 | — | — | US | disclosed |
| CN-107406462-A | Tricyclic DLK inhibitors and uses thereof | 豪夫迈·罗氏有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-106459088-A | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl amides | 辉瑞公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-105246889-A | Fluorinated integrin antagonists | SCIFLUOR LIFE SCIENCES LLC | 2016-01-13 | — | — | CN | disclosed |
| CN-104854108-A | Pyrrolotriazinone derivatives as pi3k inhibitors | ALMIRALL SA | 2015-08-19 | — | — | CN | disclosed |
| CN-103153963-B | Cyclopropane compounds | EISAI R&D MAN CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-103459384-A | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS INC | 2013-12-18 | — | — | CN | disclosed |
| CN-103153963-A | Cyclopropane compounds | EISAI R&D MAN CO LTD | 2013-06-12 | — | — | CN | disclosed |
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | BASF SE (DE) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327397-A1 | Pesticidally Active Fused Bicyclic Heteroaromatic Compounds | DDT, ACHE, GSTO1 | LMNA 2238/4885TDP1 1239/4885CHRNB2 576/4885 |
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | TPMT, NQO2, TST | LMNA 3704/4885TDP1 1991/4885CHRNB2 4814/4885 |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | P2RX7, P2RX3, P2RX1 | LMNA 1447/4885TDP1 1868/4885CHRNB2 352/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | LMNA 1370/4885TDP1 2215/4885CHRNB2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.